Publicaciones en colaboración con investigadoras/es de GlaxoSmithKline (United Kingdom) (10)

2015

  1. Safety and persistence of the humoral and cellular immune responses induced by 2 doses of an AS03-adjuvanted A(H1N1)pdm09 pandemic influenza vaccine administered to infants, children and adolescents: Two open, uncontrolled studies

    Human Vaccines and Immunotherapeutics, Vol. 11, Núm. 10, pp. 2359-2369

2013

  1. Serotype-Specific Changes in Invasive Pneumococcal Disease after Pneumococcal Conjugate Vaccine Introduction: A Pooled Analysis of Multiple Surveillance Sites

    PLoS Medicine, Vol. 10, Núm. 9

2011

  1. Combined haemophilus influenzae type B-neisseria meningitidis serogroup C vaccine is immunogenic and well tolerated in preterm infants when coadministered with other routinely recommended vaccines

    Pediatric Infectious Disease Journal, Vol. 30, Núm. 11

  2. Immunogenicity and safety of AS03-adjuvanted H1N1 pandemic vaccines in children and adolescents

    Vaccine, Vol. 29, Núm. 26, pp. 4353-4361

2010

  1. Immunogenicity and safety of AS03-adjuvanted 2009 influenza A H1N1 vaccine in children 6-35 months

    Vaccine, Vol. 28, Núm. 36, pp. 5837-5844

2009

  1. Safety and reactogenicity of the 10-valent pneumococcal non-typeable haemophilus influenzae protein D conjugate vaccine (PHiD-CV) when coadministered with routine childhood vaccines

    Pediatric Infectious Disease Journal, Vol. 28, Núm. SUPPL. 4

2003

  1. Facilitating the WHO Expanded Program of Immunization: The clinical profile of a combined diphtheria, tetanus, pertussis, hepatitis B and Haemophilus influenzae type b vaccine

    International Journal of Infectious Diseases, Vol. 7, Núm. 2, pp. 143-151

1998

  1. Vacuna tetravalente frente a difteria, tetanos, B. pertussis y hepatitis B: Experiencia en Espana

    Anales Espanoles de Pediatria, Vol. 48, Núm. 2, pp. 132-137

1997

  1. Immune response to a combined hepatitis B, diphtheria, tetanus and whole-cell pertussis vaccine administered to infants at 2, 4 and 6 months of age

    Vaccine, Vol. 15, Núm. 1, pp. 7-9

1995

  1. Safety and immunogenicity of an inactivated hepatitis A vaccine in children 2 to 5 years old

    Infection, Vol. 23, Núm. 5, pp. 334-338